Greater Glasgow and Clyde Medicines

Formulary Search Results for: CALCIUM AND VITAMIN D

If the searched medicine is not listed in the NHSGGC Formulary, please check if the relevant therapeutic chapter is now available on the West of Scotland Formulary — visit formulary.nhs.scot/west.

2.8.4 Reversal of anticoagulation - View Category

Total Formulary
Specialist Only
ANDEXANET ALFA (ONDEXXYA) (infusion)

Restrictions:

Restricted to use only on the advice of a Consultant Haematologist for the reversal of anticoagulation in adults treated with a direct factor Xa inhibitor where there is life-threatening or uncontrolled bleeding.  In addition, use should be in accordance with the local protocol (in development).

BNF Link

2.9 Antiplatelet drugs - View Category

Preferred List
DIPYRIDAMOLE (MR CAPSULES)

Restrictions:

Restricted to use in accordance with the NHSGGC Guidelines for the Secondary Prevention of Stroke and TIA

BNF Link

9.1.8 Drugs for other blood disorders - View Category

Total Formulary
Specialist Only
ETRANACOGENE DEZAPARVOVEC (Hemgenix)

Restrictions:

Restricted to specialist use for the treatment of severe and moderately severe haemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors.

BNF Link

5.3.3 Viral hepatitis - View Category

Total Formulary
Specialist and GP
TENOFOVIR DISOPROXIL

Restrictions:

Restricted to initiation by, or on the advice of, a specialist treating hepatitis B in accordance with local protocol.

Prescribing Notes:

Tenofovir for the treatment of hepatitis B is subject to an agreed Shared Care Protocol which allows the ongoing prescribing to be carried out by the patient's GP under guidance and review by the acute specialist.

To access this Shared Care Agreement, and others, click here

BNF Link

2.8.1 Parenteral anticoagulants - View Category

Total Formulary
Specialist and GP
DALTEPARIN (FRAGMIN)

Restrictions:

Restricted to specialist initiation only. The treatment and prevention of VTE in patients with solid tumours use is restricted to initiation by healthcare professionals experienced in the treatment of VTE and use according to local protocol.

Prescribing Notes:

When dalteparin is used in the extended treatment of VTE and prevention of recurrence in patients with solid tumours, prescribers are reminded that a dose reduction is required following the first month of treatment, and where there is a transfer of care, the need for this dose reduction should be communicated clearly.  For further dosing information, see the product literature or BNF.

BNF Link

4.2.2 Antipsychotic depot injections - View Category

Total Formulary
Specialist and GP
FLUPENTIXOL DECANOATE

Restrictions:

Restricted to specialist initiation only.

Prescribing Notes:

For further information, see the NHSGGC depot (LAI) algorithm.

BNF Link

4.2.2 Antipsychotic depot injections - View Category

Total Formulary
Specialist and GP
HALOPERIDOL DECANOATE (Haldol Decanoate)

Restrictions:

Restricted to specialist initiation only.

Prescribing Notes:

For further information, see the NHSGGC depot (LAI) algorithm.

BNF Link

4.2.2 Antipsychotic depot injections - View Category

Total Formulary
Specialist and GP
ZUCLOPENTHIXOL DECANOATE (Clopixol)

Restrictions:

Restricted to specialist initiation only.

Prescribing Notes:

For further information, see the NHSGGC depot (LAI) algorithm.

BNF Link

4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder - View Category

Total Formulary
Specialist and GP
DEXAMFETAMINE

Restrictions:

Restricted to second line therapy for the treatment of ADHD and initiation by child or adolescent psychiatrists or paediatricians with expertise in ADHD.

BNF Link

8.1.2 Anthracyclines and other cytotoxic antibiotics - View Category

Total Formulary
Specialist Only
DAUNORUBICIN AND CYTARABINE (LIPOSOMAL) (VYXEOS) (liposomal infusion)

Restrictions:

Restricted to specialist use in accordance with regional protocols [NHS network access required] for the following:

  • AML: The treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (AML) or AML with myelodysplasia related changes. 

BNF Link